DSIP Dosage: What the Research Actually Used (and Why There's No Established Protocol)

If you search for a DSIP dose, you will find confident numbers — usually something like "100–200 mcg subcutaneous before bed." This page exists to be honest about where those numbers come from, which is: not from any clinical protocol. Delta sleep-inducing peptide (DSIP) is not an approved drug, has never had a dosing schedule established for any condition, and the modern injection numbers circulating online are extrapolated folk dosing, not validated regimens. What follows is a description of what the actual research administered decades ago, and why that does not translate into a recommendation you can act on. This is research-only context, not medical advice — and the honest first move is a conversation with a clinician, not a number off a forum.

Why "DSIP dosage" is the wrong question

DSIP was isolated in the 1970s as a nine-amino-acid peptide named for its apparent ability to induce delta (slow-wave) sleep in rabbits. But more than four decades of work never resolved what it does in humans, how it acts, or even whether the circulating peptide is biologically active — one major review summed it up by calling DSIP "a still unresolved riddle"¹. You cannot have an established dose for a substance whose mechanism, target, and reliable effect were never pinned down. So the right framing is not "what is the DSIP dose?" but "what did the few human studies happen to administer, and how little that tells us." For the wider picture of what DSIP is and isn't, see our DSIP peptide overview.

What the old human trials actually administered

The human DSIP literature is small, old, and used intravenous administration — not the subcutaneous nighttime injection sold today. In a controlled study of severe chronic insomnia, DSIP was given by IV infusion in the range of roughly 25 nanomoles per kilogram of body weight, and the investigators reported modest, inconsistent shifts in sleep-wake behaviour rather than a clear hypnotic effect². A separate hospital-admission study likewise infused DSIP intravenously to test whether it improved sleep in a short-term setting, again finding limited, equivocal benefit³. An earlier clinical trial reported some signal but in a small, uncontrolled format that would not meet modern standards⁴. The throughline: the actual research dosed in nanomoles per kilogram, intravenously, under supervision — and even then the results were underwhelming and never replicated into a protocol.

Why the online "100–200 mcg subcutaneous" numbers are extrapolation

The injection protocols you'll see online bear almost no relationship to what was studied. They convert a vague molar figure into a fixed microgram dose, switch the route from intravenous infusion to a subcutaneous shot, and present a precise-sounding bedtime schedule — none of which any trial validated. Three problems stack up. First, route matters: an IV infusion and a subcutaneous injection produce completely different pharmacokinetics, and there is no published PK study establishing a subcutaneous DSIP dose. Second, the original trials' effects were modest and inconsistent even by IV, so extrapolating them into a confident SC regimen inherits no efficacy evidence at all¹. Third, the precision is false — a "100 mcg" instruction implies a validated target where none exists. The honest description of these protocols is folk dosing: numbers that circulate because they circulate, not because they were tested.

The grey-market measuring and sourcing problem

Layered on top of the missing protocol are the practical hazards common to any research-only peptide. DSIP sold "for research use, not for human consumption" carries no guarantee of identity, purity, or actual peptide content, and a vial labeled "5 mg" may not contain 5 mg of DSIP. Even if it did, turning that into an injected dose means reconstituting a lyophilized powder with bacteriostatic water and converting milligrams into units on an insulin syringe — the same arithmetic step where peptide users most often slip by an order of magnitude. We walk through that reconstitution math in storage & reconstitution, and our calculators can help with the concentration arithmetic as a planning aid — but no calculator can validate a dose that the science never established. For the safety picture specific to this peptide, see DSIP side effects.

The honest bottom line

There is no established DSIP dosage because DSIP is not an approved drug and its effects in humans were never reliably demonstrated. The real research administered it intravenously, in the nanomole-per-kilogram range, under supervision, with modest and inconsistent results that were never developed into a protocol. The "100–200 mcg subcutaneous at night" numbers online are extrapolated folk dosing — wrong route, false precision, no efficacy data behind them — compounded by the identity, purity, and measuring uncertainties of grey-market peptides. If sleep is the goal, the evidence-based path is not a self-dosed research peptide; start with our honest look at peptides for sleep, and if you are exploring prescriber-supervised peptide options at all, do it with a clinician who can actually monitor you. Anyone presenting a confident DSIP dose is selling certainty the science doesn't have.